GlassScriptPhysician profile
Jorge E Mendizabal
NPI 1588771950
$87,052.92
in general payments reported to CMS, 2019-2025
44 companies · $9,428 in 2025
The $9,428 reported for 2025 was more than what 89% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $14K · 2021: $15K · 2022: $6,361 · 2023: $9,870 · 2024: $13K · 2025: $9,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Food and Beverage: $3,736 · Consulting Fee: $1,825 · Travel and Lodging: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,356.25 |
| Food and Beverage | $3,735.58 |
| Consulting Fee | $1,825.00 |
| Travel and Lodging | $177.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $37,352.84 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $20,907.32 | 2019-2022 | |
| Amgen INC. | $20,884.46 | 2019-2023 | Aimovig |
| Pfizer INC. | $2,232.38 | 2023-2025 | |
| Biogen, INC. | $762.89 | 2019-2025 | Tysabri |
| Allergan, INC. | $694.47 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $554.57 | 2019-2025 | |
| Ucb, INC. | $426.17 | 2019-2023 | Briviact, Nayzilam |
| Lilly USA, LLC | $349.69 | 2019-2024 | Kisunla, Emgality |
| Lundbeck LLC | $304.20 | 2020-2025 | Vyepti, Rexulti |
| Eisai INC. | $271.43 | 2023-2025 | |
| Ge Healthcare | $172.63 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $170.92 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $147.27 | 2022 | |
| Livanova USA, INC. | $142.57 | 2021-2025 | Vns Therapy Sentiva Model 1000 Generator |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $139.13 | 2019-2023 | Ultomiris |
| Neurocrine Biosciences, INC. | $135.58 | 2023 | Ingrezza, Ongentys |
| Otsuka America Pharmaceutical, INC. | $134.93 | 2023-2025 | Rexulti, Nuedexta |
| Otter Pharmaceuticals, LLC | $131.22 | 2024-2025 | Sympazan |
| Acorda Therapeutics, INC | $106.77 | 2019 | |
| Supernus Pharmaceuticals, INC. | $106.53 | 2019 | |
| Octapharma USA, INC. | $100.00 | 2023-2025 | Panzyga |
| Emd Serono, INC. | $76.76 | 2019-2023 | Mavenclad |
| Vanda Pharmaceuticals INC. | $67.49 | 2025 | Ponvory |
| Insightec,INC | $58.94 | 2024-2025 | Exablate |
| Genentech USA, INC. | $56.01 | 2022-2023 | Ocrevus |
| Argenx US, INC. | $54.07 | 2022-2023 | Vyvgart |
| Kyowa Kirin, INC. | $50.26 | 2020-2021 | |
| Grifols USA, LLC | $47.54 | 2024-2025 | Gamunex-C |
| Acadia Pharmaceuticals INC | $46.27 | 2023-2025 | Nuplazid |
| Catalyst Pharmaceuticals, INC. | $42.67 | 2020-2024 | |
| Mdd US Operations, LLC | $41.29 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $39.04 | 2019-2020 | |
| Tg Therapeutics, INC. | $38.89 | 2025 | |
| Averitas Pharma INC. | $32.47 | 2024 | Qutenza |
| Neurelis, INC. | $31.77 | 2025 | Valtoco |
| Nevro Corp. | $20.73 | 2022 | |
| Medtronic, INC. | $19.99 | 2024 | Percept PC Brainsense |
| Amneal Pharmaceuticals LLC | $19.02 | 2025 | Crexont |
| Adamas Pharmaceuticals, INC. | $18.13 | 2020 | |
| Sk Life Science, INC. | $17.27 | 2021 | |
| Avion Pharmaceuticals | $16.95 | 2023 | Dhivy |
| Upsher-Smith Laboratories LLC | $16.04 | 2020 | |
| Arbor Pharmaceuticals, INC. | $13.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Mendizabal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.